

DAFTAR PUSTAKA

- Agoulnik, I.U. and Weigel, N.L., 2006. Androgen receptor action in hormone-dependent and recurrent prostate cancer. *Journal of cellular biochemistry*, 99(2), pp.362-372.
- Anwar, S.L., Haryono, S.J., Aryandono, T. and Haryana, S.M., 2018. *microRNA: biogenesis, fungsi, dan perannya dalam proses karsinogenesis dan penatalaksanaan kanker*. UGM PRESS.
- Armstrong, B., Barry, M., Frydenberg, M., Gardiner, R.A., Haines, I. and Carter, S.M., 2017. PSA testing for men at average risk of prostate cancer.
- Arya, M., Shergill, I.S., Williamson, M., Gommersall, L., Arya, N. and Patel, H.R., 2005. Basic principles of real-time quantitative PCR. Expert review of molecular diagnostics, 5(2), pp.209-219.
- Baietti, M.F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson, Y., Depoortere, F., Coomans, C., Vermeiren, E. and Zimmermann, P., 2012. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. *Nature cell biology*, 14(7), pp.677-685.
- Becker A., Thakur B.K., Weiss J.M., Kim H.S., Peinado H., Lyden D. Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis. *Cancer Cell*. 2016;30:836–848. Biomarkers Definitions Working Group, Atkinson Jr, A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T. and Spilker, B.A., 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clinical pharmacology & therapeutics*, 69(3), pp.89-95.
- Bobrie, A., Colombo, M., Raposo, G. and Théry, C., 2011. Exosome secretion: molecular mechanisms and roles in immune responses. *Traffic*, 12(12), pp.1659-1668.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 68(6), pp.394-424.
- Brumbaugh, C.D., Kim, H.J., Giovacchini, M. and Pourmand, N., 2011. NanoStriDE: normalization and differential expression analysis of NanoString nCounter data. *BMC bioinformatics*, 12(1), pp.1-4.
- Bryzgunova, O.E., Zaripov, M.M., Skvortsova, T.E., Lekchnov, E.A., Grigor'eva, A.E., Zaporozhchenko, I.A., Morozkin, E.S., Ryabchikova, E.I., Yurchenko, Y.B., Voitsitskiy, V.E. and Laktionov, P.P., 2016. Comparative study of

extracellular vesicles from the urine of healthy individuals and prostate cancer patients. *PLoS One*, 11(6).

Cardullo RA, Agrawal S, Flores C, Zamecnick PC, Wolf DE. 1988. Detection of nucleic acid hybridization by non-radiative fluorescence resonance energy transfer. *Proc. Natl Acad. Sci. USA* 85, 8790

Carroll, P.H. and Mohler, J.L., 2018. NCCN guidelines updates: prostate cancer and prostate cancer early detection. *Journal of the National Comprehensive Cancer Network*, 16(5S), pp.620-623.

Catalanotto, C., Cogoni, C. and Zardo, G., 2016. MicroRNA in control of gene expression: an overview of nuclear functions. *International journal of molecular sciences*, 17(10), p.1712.

Chmelar, R., Buchanan, G., Need, E.F., Tilley, W. and Greenberg, N.M., 2007. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. *International Journal of cancer*, 120(4), pp.719-733.

Chaidir, M. *et al.* 2015 'Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia / BPH)', pp. 8–33.

Chirshhev, E., Oberg, K. C., Ioffe, Y. J., & Unternaehrer, J. J. (2019). Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. *Clinical and Translational Medicine*, 8(1), 24.

Cocucci, E. and Meldolesi, J., 2015. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends in cell biology*, 25(6), pp.364-372.

Datta, M. W. 2004. 'Prostate Cancer with Low PSA Levels', *New England Journal of Medicine*, 351(17), pp. 1802–1803. doi: 10.1056/nejm200410213511724.

Davidson JH, Chutkan DS. Benign prostatic hyperplasia: treat or wait? *J Fam Pract.* 2008;57:454–63.

Dagogo-Jack, I. and Shaw, A.T., 2018. Tumour heterogeneity and resistance to cancer therapies. *Nature reviews Clinical oncology*, 15(2), p.81.

Dimitra Karagkouni, Maria D Paraskevopoulou, Serafeim Chatzopoulos, Ioannis S Vlachos, Spyros Tastsoglou, Ilias Kanellos, Dimitris Papadimitriou, Ioannis Kavakiotis, Sofia Maniou, Giorgos Skoufos, Thanasis Vergoulis, Theodore Dalamagas, Artemis G Hatzigeorgiou. 2018. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions, *Nucleic Acids Research*, Volume 46, Issue D1, Pages D239–D245, <https://doi.org/10.1093/nar/gkx1141>

Dunn, Mary Weinstein, 2017, "Prostate Cancer Screening", *Seminars in Oncology Nursing*. Vol. 33, no. 2, hal. 156–164.

- Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., Yuan, J., Chen, Z., Yang, A. and Wang, H., 2010. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. *PLoS one*, 5(4).
- Fernandez-Llama P, Khositseth S, Gonzales PA, Star RA, Pisitkun T & Knepper MA (2010). Tamm-Horsfall protein and urinary exosome isolation. *Kidney Int* 77, 736–742.
- Fernandez-Serra, A., Casanova-Salas, I., Rubio, L., Calatrava, A., García-Flores, M., García-Casado, Z., Lopez-Guerrero, J.A. and Rubio-Briones, J., 2015. Update on the diagnosis of PCa in urine. The current role of urine markers. *Archivos espanoles de urologia*, 68(3), pp.240-249.
- Fiedler, S. D., Carletti, M. Z., & Christenson, L. K. (2010). Quantitative RT-PCR methods for mature microRNA expression analysis. In *RT-PCR Protocols* (pp. 49-64). Humana Press, Totowa, NJ.
- Fraga, D., Meulia, T. and Fenster, S., 2008. Real-time PCR. *Current protocols essential laboratory techniques*, (1), pp.10-3.
- GLOBOCAN. 2018. <https://gco.iarc.fr/today/>. Diakses pada 29 Juli 2020
- Hamilton, G. and O'Neill, E., 2013. Hippo pathway and apoptosis. In *The Hippo Signaling Pathway and Cancer* (pp. 117-145). Springer, New York, NY.
- Hasibe Vural, Ercan Kurar, Ebru Avci, et al. KRAS Mutations: A Possible Biomarker for Advanced Prostate Cancer. *Cancer Sci Res*. 2018; 1(3); 1-4. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, et al. Current state of circulating microRNAs as cancer biomarkers. *Clin Chem* 2015;61:1138-55.
- He, L. and Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene regulation. *Nature Reviews Genetics*, 5(7), pp.522-531.
- Heneghan, H.M., Miller, N., Lowery, A.J., Sweeney, K.J., Newell, J. and Kerin, M.J., 2010. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. *Annals of surgery*, 251(3), pp.499-505.
- Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.P., van der Kwast, T., Wiegel, T. and Zattoni, F., 2011. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. *European urology*, 59(1), pp.61-71.
- Hata, A. and Lieberman, J., 2015. Dysregulation of microRNA biogenesis and gene silencing in cancer. *Sci. Signal.*, 8(368), pp.re3-re3. Huntzinger, E. and Izaurralde, E., 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nature Reviews Genetics*, 12(2), pp.99-110.

- Huang, X.; Yuan, T.; Tschannen, M.; Sun, Z.; Jacob, H.; Du, M.; Liang, M.; Dittmar, R.L.; Liu, Y.; Liang, M.; et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genom.* 2013, 14, 319
- Hoey, C., & Liu, S. K. (2019). Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies. *Research and reports in urology*, 11, 29.
- Ilic, D., Neuberger, M.M., Djulbegovic, M. and Dahm, P., 2013. Screening for prostate cancer. *Cochrane Database of Systematic Reviews*, (1).
- Jella, K.K., Nasti, T.H., Li, Z., Malla, S.R., Buchwald, Z.S. and Khan, M.K., 2018. Exosomes, their biogenesis and role in inter-cellular communication, tumor microenvironment and cancer immunotherapy. *Vaccines*, 6(4), p.69
- Janas, T., Janas, M.M., and Sapoń, K. 2015. Mechanisms of RNA loading into exosomes. *FEBS letters*, 589(13), pp.1391-1398.
- Kalluri, R., 2016. The biology and function of exosomes in cancer. *The Journal of clinical investigation*, 126(4), pp.1208-1215.
- Keller, S., Ridinger, J., Rupp, A.K., Janssen, J.W. and Altevogt, P., 2011. Body fluid derived exosomes as a novel template for clinical diagnostics. *Journal of translational medicine*, 9(1), p.86.
- Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., et al. (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc. Natl. Acad. Sci. U.S.A.* 113, E968–E977. doi: 10.1073/pnas.1521230113
- Kozera, B. and Rapacz, M., 2013. Reference genes in real-time PCR. *Journal of applied genetics*, 54(4), pp.391-406.
- Lappin, S., Gomez, M., Knorr, D., 2012, Complete Automation of the Stratagene StrataPrep 96 PCR Purification Kit with the Agilent Bravo Automated Liquid Handling Platform and Agilent Automated Centrifuge, Agilent Technologies, Inc. Santa Clara, CA USA.
- Larrea, E., Sole, C., Manterola, L., Goicoechea, I., Armesto, M., Arestin, M., & Lawrie, C. H. (2016). New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. *International journal of molecular sciences*, 17(5), 627.
- Lee, H., Han, S., Kwon, C.S. and Lee, D., 2016. Biogenesis and regulation of the let-7 miRNAs and their functional implications. *Protein & cell*, 7(2), pp.100-113.
- Lee, Y., El Andaloussi, S. and Wood, M.J., 2012. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. *Human molecular genetics*, 21(R1), pp.R125-R134.

- Li, N., Xie, C. and Lu, N., 2017. Crosstalk between Hippo signalling and miRNAs in tumour progression. *The FEBS journal*, 284(7), pp.1045-1055.
- Mathai, R.A., Vidya, R.V.S., Reddy, B.S., Thomas, L., Udupa, K., Kolesar, J. and Rao, M., 2019. Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: implications in the precision oncology. *Journal of clinical medicine*, 8(3), p.373.
- Madersbacher, S., Sampson, N. and Culig, Z., 2019. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. *Gerontology*, 65(5), pp.458-464.
- Mathivanan, S., Ji, H. and Simpson, R.J., 2010. Exosomes: extracellular organelles important in intercellular communication. *Journal of proteomics*, 73(10), pp.1907-1920.
- Meng, Z.; Moroishi, T.; Guan, K.L. Mechanisms of Hippo pathway regulation. *Genes Dev.* 2016, 30, 1–17. [CrossRef] [PubMed]
- Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S et al. (2014) microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. *Mol Cancer*.
- Morgan, E.L., Patterson, M.R., Ryder, E.L., Lee, S.Y., Wasson, C.W., Harper, K.L., Li, Y., Griffin, S., Blair, G.E., Whitehouse, A. and Macdonald, A., 2020.
- MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer. *PLoS pathogens*, 16(6), p.e1008624.
- Nandeesh, H., 2008. Benign prostatic hyperplasia: dietary and metabolic risk factors. *International urology and nephrology*, 40(3), pp.649-656.
- NanoString Technologies, Inc. Total RNA and Cell Lysate Protocols. nCounter™ Gene Expression Assay Manual. 2009
- NanoString. 2018. nCounter® miRNA Expression Assay User Manual. <https://www.nanostring.com/>
- Ning Y, Xu M, Cao X, Chen X, Luo X. Inactivation of AKT, ERK and NF-κB by genistein derivative, 7-difluoromethoxyl-5,4'-di-n-octylgenistein, reduces ovarian carcinoma oncogenicity. *Oncol Rep.* 2017;38:949–958 Nishiguchi, M. K. et al. (2002) *Techniques in Molecular Systematics and Evolution, Techniques in Molecular Systematics and Evolution*. doi: 10.1007/978-3-0348-8125-8.
- Ovarian, C. et al. (2016) ‘Ovarian Cancer Early Detection ,Diagnosis , and Staging Can Ovarian Cancer Be Found Early ?’, pp. 1–25.

- Perron, M.P. and Provost, P., 2008. Protein interactions and complexes in human microRNA biogenesis and function. *Frontiers in bioscience: a journal and virtual library*, 13, p.2537.
- Pullar Ben dan Nimish Shah, 2016, "Prostate cancer". *Renal And Urological Surgery*
- IParsons, J.K., 2010. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. *Current bladder dysfunction reports*, 5(4), pp.212-218.
- Paraskevopoulou, M.D., Vlachos, I.S. and Hatzigeorgiou, A.G., 2016. DIANA-TarBase and DIANA Suite Tools: Studying Experimentally Supported microRNA Targets. *Current protocols in bioinformatics*, 55(1), pp.12-14.
- Park, J.K., Doseff, A.I. and Schmittgen, T.D., 2018. MicroRNAs targeting caspase-3 and-7 in PANC-1 cells. *International journal of molecular sciences*, 19(4), p.1206.
- Rawla, P. (2019) 'Epidemiology of Prostate Cancer', (April). doi: 10.14740/wjon1191.
- Roehrborn, C., 2012. Benign prostatic hyperplasia and lower urinary tract symptom guidelines. *Canadian Urological Association Journal*, 6(5 Suppl 2), p.S130.
- Rennie, W., Liu, C., Carmack, C. S., Wolenc, A., Kanoria, S., Lu, J., ... & Ding, Y. (2014). STarMir: a web server for prediction of microRNA binding sites. *Nucleic acids research*, 42(W1), W114-W118.
- Santos, C.G., Melo, V.S., Amaral, J.S., Estevinho, L., Oliveira, M.B.P.P., Mafra, I., 2012, Identification of hare meat by a species-specific marker of mitochondrial origin, *Meat Science*, 90, 836–841.
- Seifi, M., Ghasemi, A., Heidarzadeh, S., Khosravi, M., Namipashaki, A., Soofiany, V.M., Khosroshahi, A.A. and Danaei, N., 2012. Overview of Real-Time PCR Principles. *Polymerase Chain Reaction*, pp.405-442.
- Servín-González, L.S., Granados-López, A.J. and López, J.A., 2015. Families of microRNAs expressed in clusters regulate cell signaling in cervical cancer. *International journal of molecular sciences*, 16(6), pp.12773-12790.
- Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. *Nat Commun*. 2013; 4:2976.
- Shen, P., Zeng, H., Ortiz, A., Cheng, C. J., Lee, Y. C., Yu, G., ... & Lin, S. H. (2017). Angiotensin II to regulate prostate cancer cell proliferation by signaling through Hippo-YAP pathway.
- Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., & Jensen, L. J. (2016). The STRING database in 2017: quality-controlled protein–

- protein association networks, made broadly accessible. *Nucleic acids research*, gkw937.
- Sokolenko, A. P. and Imyanitov, E. N. 2018. ‘Molecular diagnostics in clinical oncology’, *Frontiers in Molecular Biosciences*, 5(AUG), pp. 1–15. doi: 10.3389/fmolb.2018.00076.
- Song JJ, Lee YJ. Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. *Cell Signal*. 2008;20:892–906.
- Suzuki, H.I., Matsuyama, H., Noguchi, M., Yao, T., Komatsu, N., Mano, H., Sugimoto, K. and Miyazono, K., 2013. Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. *Leukemia*, 27(10), pp.2107-2111.
- Schwarzenbach, H. and Gahan, P.B., 2019. MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer. *Non-coding RNA*, 5(1), p.28.
- Svoronos, A.A., Engelman, D.M. and Slack, F.J., 2016. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. *Cancer research*, 76(13), pp.3666-3670.
- Thiruchelvam, N., 2014. Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. *Indian journal of urology: IJU: journal of the Urological Society of India*, 30(2), p.202.
- Thomas, C.E., Sexton, W., Benson, K., Sutphen, R. and Koomen, J., 2010. Urine collection and processing for protein biomarker discovery and quantification. *Cancer Epidemiology and Prevention Biomarkers*, 19(4), pp.953-959.
- Tim Cutcliffe. 2018. <https://www.nutraingredients.com/Article/2018/01/19/High-fat-diet-linked-to-prostate-cancer-spread>. Diakses 25 agustus 2020.
- Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A., 2015. Global cancer statistics, 2012. *CA: a cancer journal for clinicians*, 65(2), pp.87-108.
- Tsang, W. P., & Kwok, T. T. (2008). Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. *Apoptosis*, 13(10), 1215–1222. doi:10.1007/s10495-008-0256-z
- Ovarian, C. *et al.* (2016) ‘Ovarian Cancer Early Detection , Diagnosis , and Staging Can Ovarian Cancer Be Found Early ?’, pp. 1–25.
- Quek, S.I., Wong, O.M., Chen, A., Borges, G.T., Ellis, W.J., Salvanha, D.M., Vêncio, R.Z., Weaver, B., Ench, Y.M., Leach, R.J. and Thompson, I.M., 2015. Processing of voided urine for prostate cancer RNA biomarker analysis. *The Prostate*, 75(16), pp.1886-1895.

- Varelas, X. (2014). The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. *Development*, 141(8), 1614-1626. Vanacore, D. et al. 2017. 'MicroRNAs in prostate cancer: An overview', *Oncotarget*, 8(30), pp. 50240–50251. doi: 10.18632/oncotarget.16933.
- Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J. and Lötvall, J.O., 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature cell biology*, 9(6), pp.654-659.
- Venesio, Tiziana, Giulia Siravegna, Alberto Bardelli, and Anna Sapino. 2018. Liquid biopsies for monitoring temporal genomic heterogeneity in breast and colon cancers. *Pathobiology* 85, no. 1-2:146-154.
- Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., & Prueitt, R. L. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences*, 103(7), 2257-2261.
- Wagner, S., Ngezahayo, A., Murua Escobar, H. and Nolte, I., 2014. Role of miRNA let-7 and its major targets in prostate cancer. *BioMed research international*, 2014.
- Wei, J.T., Calhoun, E. and Jacobsen, S.J., 2005. Urologic diseases in America project: benign prostatic hyperplasia. *The Journal of urology*, 173(4), pp.1256-1261.
- Wilson, T. (1997) 'Benign prostatic hyperplasia [2]', *British Journal of General Practice*, 47(419), p. 401. Willenbrock, S., Wagner, S., Reimann-Berg, N., Moulay, M., Hewicker-Trautwein, M., Nolte, I. and Escobar, H.M., 2014. Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model. *PloS one*, 9(6).
- Winter, R.N., Kramer, A., Borkowski, A. and Kyprianou, N., 2001. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. *Cancer research*, 61(3), pp.1227-1232. Yang et al. (2014)
- Yang Q, Ali HA, Yu S, Zhang L, Li X, Du Z, Zhang G. Evaluation and validation of the suitable control genes for quantitative PCR studies in plasma DNA for noninvasive prenatal diagnosis. *International Journal of Molecular Medicine*. 2014;34:1681–1687. doi: 10.3892/ijmm.2014.1944.
- Yuan, J.S., Reed, A., Chen, F. and Stewart, C.N., 2006. Statistical analysis of real-time PCR data. *BMC bioinformatics*, 7(1), p.85.
- Zhang, X., Abdelrahman, A., Vollmar, B. and Zechner, D., 2018. The ambivalent function of YAP in apoptosis and cancer. *International journal of molecular sciences*, 19(12), p.3770.

Zhou, K., Liu, M. and Cao, Y., 2017. New insight into microRNA functions in cancer: oncogene–microRNA–tumor suppressor gene network. *Frontiers in molecular biosciences*, 4, p.46.